Supplementary file 1_Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.docx
Background<p>The aim of this study was to investigate the mechanism of the Poly ADP-ribose polymerase (PARP) inhibitor pamiparib (PAM) and the tyrosine kinase inhibitor anlotinib (ANL), utilizing a Biological Factor Regulatory Neural Network (BFReg-NN) and metabolomics approach.</p>Metho...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , |
| Publicado: |
2025
|
| Materias: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|